Bioventus Inc (BVS)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Bioventus Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 8 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 13.20 $ — 100% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 3.5% failed
- More than 10% revenue growth is expected for the coming year 6.6% failed
- Share count grows by less than 3% a year 3.9% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 11.7% failed
- Gross margin at 40% or higher and without meaningful erosion 67.3% passed
- Goodwill from acquisitions does not grow faster than revenue 1.1% passed
- Net debt below twice EBITDA 2.6 x EBITDA failed
- Operating cash flow covers the profits of the last three years 295 m passed
- Return on capital at 15% or higher, or up versus two years ago 11.2% passed
- Insiders hold at least 10% or are net buyers 11.8% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 12.1% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 3
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.78 | 0.77 – 0.79 | 606 | 14.7% | 5 |
| 12/31/2027 | 0.91 | 0.87 – 0.97 | 646 | 16.4% | 5 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.22 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.00 | – | 154 | 13.50 | -0.10 | 19 | 19 |
| 2025: Q1 | -0.04 | – | 124 | -4.30 | -2.10 | -19 | -20 |
| 2025: Q2 | 0.11 | – | 148 | -2.40 | 5.10 | 26 | 25 |
| 2025: Q3 | 0.05 | – | 139 | -0.20 | 2.30 | 30 | 30 |
| 2025: Q4 | 0.21 | – | 158 | 2.80 | 9.30 | 38 | 37 |
| 2026: Q1 | 0.04 | – | 132 | 6.60 | 2.40 | 9 | 8 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 275 | 15 | -18 | -0.32 | – | – | – |
| 2017 | 292 | 27 | -2 | -0.03 | – | – | – |
| 2018 | 319 | 26 | -12 | -0.21 | 45 | 145 | 443 |
| 2019 | 340 | 31 | 7 | 0.12 | 41 | 143 | 472 |
| 2020 | 321 | 21 | 16 | 0.44 | 72 | 142 | 494 |
| 2021 | 431 | 12 | 19 | 0.43 | 23 | 459 | 1,226 |
| 2022 | 512 | -167 | -159 | -2.59 | -14 | 325 | 1,373 |
| 2023 | 512 | -82 | -156 | -2.49 | 15 | 174 | 811 |
| 2024 | 573 | -12 | -34 | -0.51 | 39 | 148 | 728 |
| 2025 | 568 | 59 | 23 | 0.33 | 74 | 184 | 684 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Bioventus Inc., ein Medizinprodukteunternehmen, konzentriert sich auf Schmerzlinderung und muskuloskelettale Therapien in den USA und international.
| Employees | 940 |
|---|---|
| Headquarters | Durham, NC |
| Address | 4721 Emperor Boulevard, 27703 Durham, United States |
| Phone | 919 474 6700 |
| Website | bioventus.com |
| IPO Date | 11. Feb 2021 |
| ISIN | US09075A1088 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Robert E. Claypoole | President, CEO & Director | 1972 |
| Mark L. Singleton | Senior VP & CFO | 1969 |
| Anthony D'Adamio J.D. | Senior VP, General Counsel & Corporate Secretary | 1961 |
| Mike Crowe B.S., M.B.A. | Senior Vice President of Operations | – |
| David Crawford | Vice President of Investor Relations & Treasurer | – |
| Katrina J. Church J.D. | Senior VP & Chief Compliance Officer | 1962 |
| Helen Leupold | Senior VP & Chief Human Resources Officer | – |
| Dave Venner | Senior VP & GM of Surgical | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.